|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kievit FM, Wang FY, Fang C, Mok H, Wang K,
Silber JR, Ellenbogen RG and Zhang M: Doxorubicin loaded iron oxide
nanoparticles overcome multidrug resistance in cancer in vitro. J
Control Release. 152:76–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan XL, Moyer AM, Fridley BL, Schaid DJ,
Niu N, Batzler AJ, Jenkins GD, Abo RP, Li L, Cunningham JM, et al:
Genetic variation predicting cisplatin cytotoxicity associated with
overall survival in lung cancer patients receiving platinum-based
chemotherapy. Clin Cancer Res. 17:5801–5811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and de Grève J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancercells. PLoS One. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/Akt/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li L, Wei XH, Pan YP, Li HC, Yang H, He
QH, Pang Y, Shan Y, Xiong FX, Shao GZ and Zhou RL: LAPTM4B: A novel
cancer-associated gene motivates multidrug resistance through
efflux and activating PI3K/Akt signaling. Oncogene. 29:5785–5795.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin X, Zhang X, Wang Q, Li J, Zhang P,
Zhao M and Li X: Perifosine downregulates MDR1 gene expression and
reverses multidrug-resistant phenotype by inhibiting
PI3K/Akt/NF-kappaB signaling pathway in a human breast cancer cell
line. Neoplasma. 59:248–256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lasorella A, Uo T and Iavarone A: Id
proteins at the cross-road of development and cancer. Oncogene.
20:8326–8333. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ruzinova MB and Benezra R: Id proteins in
development, cell cycle and cancer. Trends Cell Biol. 13:410–418.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rotzer D, Krampert M, Sulyok S, Braun S,
Stark HJ, Boukamp P and Werner S: Id proteins: Novel targets of
activin action, which regulate epidermal homeostasis. Oncogene.
25:2070–2081. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Simbulan-Rosenthal CM, Daher A, Trabosh V,
Chen WC, Gerstel D, Soeda E and Rosenthal DS: ID3 induces a
caspase-3- and −9-dependent apoptosis and mediates UVB
sensitization of HPV16 E6/7 immortalized human keratinocytes.
Oncogene. 25:3649–3660. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen YS, Aubee J, DiVito KA, Zhou H, Zhang
W, Chou FP, Simbulan-Rosenthal CM and Rosenthal DS: ID3 induces an
Elk-1-caspase-8-dependent apoptotic pathway in squamous carcinoma
cells. Cancer Med. 4:914–924. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li XJ, Zhu CD, Yu W, Wang P, Chen FF, Xia
XY and Luo B: Overexpression of ID3 induces apoptosis of A549 human
lung adenocarcinoma cells. Cell Prolif. 45:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen FF, Liu Y, Wang F, Pang XJ, Zhu CD,
Xu M, Yu W and Li XJ: Effects of up-regulation of ID3 in human lung
adenocarcinoma cells on proliferation, apoptosis, mobility and
tumorigenicity. Cancer Gene Ther. 22:431–437. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen F, Zhao Q, Wang S, Wang H and Li X:
Upregulation of ID3 inhibits cell proliferation and induces
apoptosis in A549/DDP human lung cancer cells in vitro. Mol Med
Rep. 14:313–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krystal GW, Sulanke G and Litz J:
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks
growth, promotes apoptosis, and enhances sensitivity of small cell
lung cancer cells to chemotherapy. Mol Cancer Ther. 1:913–922.
2002.PubMed/NCBI
|
|
21
|
Schmitz R, Young RM, Ceribelli M, Jhavar
S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, et
al: Burkitt lymphoma pathogenesis and therapeutic targets from
structural and functional genomics. Nature. 490:116–120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kee BL, Rivera RR and Murre C: ID3
inhibits B lymphocyte progenitor growth and survival in response to
TGF-β. Nat Immunol. 2:242–247. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ellmeier W, Aguzzi A, Kleiner E, Kurzbauer
R and Weith A: Mutually exclusive expression of a helix loop-helix
gene and N-myc in human neuroblastom as and in normal development.
EMBO J. 11:2563–2571. 1992.PubMed/NCBI
|
|
24
|
Lee YS, Mollah ML, Sohn KC, Shi G, Kim DH,
Kim KH, Cho MJ, Kim S, Lee YH, Kim CD and Lee JH: ID3 mediates
X-ray-induced apoptosis of keratinocytes through the regulation of
β-catenin. J Dermatol Sci. 60:138–142. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sachindra Larribère L, Novak D, Wu H,
Hüser L, Granados K, Orouji E and Utikal J: New role of ID3 in
melanoma adaptive drug-resistance. Oncotarget. 8:110166–110175.
2017.PubMed/NCBI
|
|
26
|
Koyama T, Suzuki H, Imakiire A, Yanase N,
Hata K and Mizuguchi J: ID3-mediated enhancement of
cisplatin-induced apoptosis in a sarcoma cell line MG-63.
Anticancer Res. 24:1519–1524. 2004.PubMed/NCBI
|
|
27
|
Ponz-Sarvisé M, Nguewa PA, Pajares MJ,
Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II,
García-Franco CE, et al: Inhibitor of differentiation-1 as a novel
prognostic factor in NSCLC patients with adenocarcinoma histology
and its potential contribution to therapy resistance. Clin Cancer
Res. 17:4155–4166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Zhang CH, Hong YL, Li J, Hu YM and
Zhao CF: Inhibitor of DNA-binding-1/inhibitor of differentiation-1
(ID-1) is implicated in various aspects of gastric cancer cell
biology. Mol Biol Rep. 39:3009–3015. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Castañon E, Bosch-Barrera J, López I,
Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A
and Gil-Bazo I: Id1 and ID3 co-expression correlates with clinical
outcome in stage III-N2 non-small cell lung cancer patients treated
with definitive chemoradiotherapy. J Transl Med. 11:132013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoon SS, Ahn KS, Kim SH, Shim YM and Kim
J: In vitro establishment of cis-diammine-dichloroplatinum (II)
resistant lung cancer cell line and modulation of apoptotic gene
expression as a mechanism of resistant phenotype. Lung Cancer.
33:221–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ozben T: Mechanisms and strategies to
overcome multiple drug resistance in cancer. FEBS Lett.
580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grise F, Sena S, Bidaud-Meynard A, Baud J,
Hiriart JB, Makki K, Dugot-Senant N, Staedel C, Bioulac-Sage P,
Zucman-Rossi J, et al: Rnd3/RhoE is down-regulated in
hepatocellular carcinoma and controls cellular invasion.
Hepatology. 55:1766–1775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang H, Wang Y, Liang B, He F, Li Y, Che
J, Li X, Zhao H and Shi G: The Rho GTPase RhoE exerts
tumor-suppressing effects in human esophageal squamous cell
carcinoma via negatively regulating epidermal growth factor
receptor. J Cancer Res Ther. 12:(Suppl):. S60–S63. 2016. View Article : Google Scholar
|
